Arrowhead Pharma Shares Close Up 24.7% On No News, But Breakout Above $4 Resistance Level; Stock Up 40+% Since Announcing Filing For Regulatory Clearance Of ARO-AAT, ARO-HBV On Dec. 20, Dec. 22, Respectively